文献速递淋巴瘤

地拉罗司通过ROS与GSK3β依赖机制诱导套细胞淋巴瘤cyclin D1降解及凋亡

Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
PubMed 文献 · Br J Haematol · 2021-01-31

本研究在套细胞淋巴瘤(MCL)细胞系及患者细胞中证实,临床可用浓度的铁螯合剂地拉罗司(DFX)可抑制生长、阻滞细胞周期并诱导凋亡。DFX通过快速诱导活性氧(ROS)引发氧化应激和DNA损伤,并经由ROS抑制PI3K/AKT/GSK3β通路,促进GSK3β磷酸化cyclin D1的T286位点,触发其蛋白酶体降解。结果提示DFX可能成为MCL的潜在治疗选择。

要点

  • DFX在临床可行浓度下对MCL细胞系和患者细胞有抗肿瘤作用。
  • DFX通过ROS依赖机制诱导氧化应激、DNA损伤和凋亡。
  • DFX经PI3K/AKT/GSK3β通路促进cyclin D1 T286磷酸化及降解。

核心结论

  • 地拉罗司在MCL细胞系和患者细胞中展现抗肿瘤活性,提示其可能成为MCL的潜在治疗选择。

研究设计与样本

  • 研究在MCL细胞系和患者细胞中评估地拉罗司的抗肿瘤效应及机制。

主要发现

  • 临床可行浓度的DFX导致MCL细胞生长抑制、细胞周期阻滞和凋亡诱导。
  • DFX快速诱导ROS,引起氧化应激和严重DNA损伤。
  • DFX通过ROS生成抑制PI3K/AKT/GSK3β通路,促进GSK3β对cyclin D1 T286的磷酸化,触发cyclin D1蛋白水解。

临床怎么用

  • DFX作为已获批的铁螯合剂,其抗MCL机制为临床转化提供了依据,但需进一步体内及临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is a difficult-to-treat B-cell malignancy characterized by cyclin D1 (CD1) overexpression. Targeting CD1 in MCL has been shown to be of therapeutic significance. However, treatment of MCL remains challenging since patients are still subject to early and frequent relapse of the disease. To ensure their high proliferation rate, tumour cells have increased iron needs, making them more susceptible to iron deprivation. Indeed, several iron chelators proved to be effective anti-cancer agents. In this study, we demonstrate that the clinically approved iron chelator deferasirox (DFX) exerts an anti-tumoural effect in MCL cell lines and patient cells. The exposure of MCL cells to clinically feasible concentrations of DFX resulted in growth inhibition, cell cycle arrest and induction of apoptosis. We show that DFX unfolds its cytotoxic effect by a rapid induction of reactive oxygen species (ROS) that leads to oxidative stress and severe DNA damage and by triggering CD1 proteolysis in a mechanism that requires its phosphorylation on T286 by glycogen synthase kinase-3β (GSK3β). Moreover, we demonstrate that DFX mediates CD1 proteolysis by repressing the phosphatidylinositol 3-kinase (PI3K)/AKT/GSK3β pathway via ROS generation. Our data suggest DFX as a potential therapeutic option for MCL and paves the way for more treatment options for these patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Samara A, Shapira S, Lubin I, et al. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism. Br J Haematol. 2021. PMID: 33521925. doi:10.1111/bjh.17284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。